GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare, severe psoriasis
Disease control CompletedThis Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The ma…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug spesolimab under Real-World watch for rare skin disease
Disease control CompletedThis study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for rare skin Flare-Ups: drug offered to those with no options
Disease control CompletedThis program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug rapidly clears pustules in rare psoriasis flare
Disease control CompletedThis study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The drug aims to quickly clear skin pustules. Results showed that more patients receiving spesolimab had no visible pustules after one wee…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising early results for rare psoriasis drug
Disease control CompletedThis study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
New shot could stop GPP flares before they start
Prevention CompletedThis study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC